MTOR and urinary bladder carcinoma: Other drugs under current investigation to treat recurrent or refractory bladder cancer include the pan-FGFR inhibitors BGJ398 [3] and AZD4547 [4], aimed at tumors with FGFR3 mutation or fusion, and the mTOR inhibitor everolimus for refractory bladder carcinoma [5].